Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
Nanjing Leads Biolabs Co (FRA:0DX) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Nanjing Leads Biolabs Co 14-Day RSI Related Terms
FRA:0DX vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's 14-Day RSI falls into.
Nanjing Leads Biolabs Co (FRA:0DX) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (FRA:0DX) has a 14-Day RSI of 54.38 as of Aug. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Nanjing Leads Biolabs Co and its competitors. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #969 out of 1420 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Nanjing Leads Biolabs Co's 14-Day RSI too high?
Nanjing Leads Biolabs Co's current 14-Day RSI is 54.38. The Biotechnology industry median 14-Day RSI is 49.98. Nanjing Leads Biolabs Co's value of 54.38 is 8.8% above this industry median. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #969 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #969 out of 1420 companies for 14-Day RSI. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median 14-Day RSI is 49.98. Nanjing Leads Biolabs Co's value of 54.38 is 8.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.98, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Leads Biolabs Co's current 14-Day RSI of 54.38 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current 14-Day RSI is 54.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current 14-Day RSI of 54.38. The current 14-Day RSI is 54.38 and 8.8% above the Biotechnology industry median of 49.98. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current 14-Day RSI is 54.38 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
